Instrumented gait analysis defines the walking signature of CACNA1A disorders.
CACNA1A
Episodic ataxia type 2
Familial hemiplegic migraine type 1
Gait analysis
Wearable sensors
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
11
07
2021
accepted:
26
10
2021
revised:
25
10
2021
pubmed:
11
11
2021
medline:
24
5
2022
entrez:
10
11
2021
Statut:
ppublish
Résumé
Gait disturbances are a frequent symptom in CACNA1A disorders. Even though, data about their severity and progression are lacking and no CACNA1A-specific scale or assessment for gait is available. We applied a gait assessment protocol in 20 ambulatory patients with genetically confirmed CACNA1A disorders and 39 matched healthy controls. An instrumented gait analysis (IGA) was performed by means of wearable sensors in basal condition and after a treadmill/cycloergometer challenge in selected cases. CACNA1A patients displayed lower gait speed, shorter steps with increased step length variability, a reduced landing acceleration as well as a reduced range of ankle motion compared to controls. Furthermore, gait-width in patients with episodic CACNA1A disorders was narrower as compared to controls. In one patient experiencing mild episodic symptoms after the treadmill challenge, the IGA was able to detect a deterioration over all gait parameters. In CACNA1A patients, the IGA with wearable sensors unravels specific gait signatures which are not detectable at naked eye. These features (narrow-based gait, lower landing acceleration) distinguish these patients from other ataxic disorders and may be target of focused rehabilitative interventions. IGA can potentially be applied to monitor the neurological fluctuations associated with CACNA1A disorders.
Sections du résumé
BACKGROUND
BACKGROUND
Gait disturbances are a frequent symptom in CACNA1A disorders. Even though, data about their severity and progression are lacking and no CACNA1A-specific scale or assessment for gait is available.
METHODS
METHODS
We applied a gait assessment protocol in 20 ambulatory patients with genetically confirmed CACNA1A disorders and 39 matched healthy controls. An instrumented gait analysis (IGA) was performed by means of wearable sensors in basal condition and after a treadmill/cycloergometer challenge in selected cases.
RESULTS
RESULTS
CACNA1A patients displayed lower gait speed, shorter steps with increased step length variability, a reduced landing acceleration as well as a reduced range of ankle motion compared to controls. Furthermore, gait-width in patients with episodic CACNA1A disorders was narrower as compared to controls. In one patient experiencing mild episodic symptoms after the treadmill challenge, the IGA was able to detect a deterioration over all gait parameters.
CONCLUSIONS
CONCLUSIONS
In CACNA1A patients, the IGA with wearable sensors unravels specific gait signatures which are not detectable at naked eye. These features (narrow-based gait, lower landing acceleration) distinguish these patients from other ataxic disorders and may be target of focused rehabilitative interventions. IGA can potentially be applied to monitor the neurological fluctuations associated with CACNA1A disorders.
Identifiants
pubmed: 34755206
doi: 10.1007/s00415-021-10878-y
pii: 10.1007/s00415-021-10878-y
pmc: PMC9120104
doi:
Substances chimiques
CACNA1A protein, human
0
Calcium Channels
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2941-2947Informations de copyright
© 2021. The Author(s).
Références
J Neurol Neurosurg Psychiatry. 1998 Oct;65(4):565-8
pubmed: 9771787
Lancet Neurol. 2015 Nov;14(11):1101-8
pubmed: 26377379
Mov Disord. 2014 Feb;29(2):252-5
pubmed: 24301795
Brain Behav. 2018 Jun;8(6):e00977
pubmed: 29733529
Brain Sci. 2019 Feb 06;9(2):
pubmed: 30736374
Gait Posture. 2019 Sep;73:305-314
pubmed: 31415979
IEEE Trans Biomed Eng. 2015 Apr;62(4):1089-97
pubmed: 25389237
Mov Disord. 2021 Nov;36(11):2559-2568
pubmed: 34109682
J R Soc Interface. 2011 Dec 7;8(65):1682-98
pubmed: 21880615
Proc Natl Acad Sci U S A. 2011 Sep 20;108(38):16068-73
pubmed: 21911381
Eur J Neurol. 2019 Jan;26(1):66-e7
pubmed: 30063100
N Engl J Med. 2001 Jul 5;345(1):17-24
pubmed: 11439943
Front Neurol. 2021 Mar 02;12:639994
pubmed: 33737904
Neurology. 2004 Jan 13;62(1):17-22
pubmed: 14718690
Cerebellum. 2012 Mar;11(1):155-66
pubmed: 21701895
J Neurol. 2021 Jul;268(7):2493-2505
pubmed: 33544220
J Comp Neurol. 1993 Feb 15;328(3):364-76
pubmed: 8440786
J Neurol. 2020 Nov;267(11):3169-3176
pubmed: 31119450
Nat Rev Neurol. 2018 Mar;14(3):183-189
pubmed: 29377011
J Neurol. 2011 Sep;258(9):1708-11
pubmed: 21431381